Edgewise Therapeutics, Inc. (EWTX)

Market Cap	1.41B
Revenue (ttm)	n/a
Net Income (ttm)	-146.09M
Shares Out	105.20M
EPS (ttm)	-1.55
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	464,606
Open	13.95
Previous Close	13.93
Day's Range	13.30 - 14.04
52-Week Range	10.60 - 38.12
Beta	0.26
Analysts	Buy
Price Target	39.89 (+198.13%)
Earnings Date	Aug 7, 2025

About EWTX

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical tria...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 26, 2021
• Employees: 110
• Stock Exchange: NASDAQ
• Ticker Symbol: EWTX
• Website: https://edgewisetx.com

Analyst Summary

According to 9 analysts, the average rating for EWTX stock is "Buy." The 12-month stock price target is $39.89, which is an increase of 198.13% from the latest price.

Price Target

$39.89

(198.13% upside)

Analyst Consensus: Buy